Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self ...

Bisphenol (BPA) affects brain development, hyperactivity, aggression - ADHD?
Examiner.com
It seems that Bisphenol A (BPA), a key ingredient of polycarbonate – clear, shatter-resistant plastic and epoxy resins – may adversely affect brain ...